Bronstein, Gewirtz & Grossman, LLC Investigates LifeSciences Holdings Corp.

Headline should read Bronstein, Gewirtz & Grossman, LLC Investigates Integra LifeSciences Holdings Corp. (sted Bronstein, Gewirtz & Grossman, LLC Investigates LifeSciences Holdings Corp.)

The corrected release reads:


Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Integra LifeSciences Holdings, Corp. (“Integra” or the “Company”) (NASDAQ:IART), concerning whether the company and certain of its officers and directors have violated federal securities laws.

On Friday, January 6, 2012, shares of Integra, a maker of orthopedic implants, fell $6.01 or almost 20% to close at $24.49 after cutting its revenue forecast and saying U.S. regulators cited the company for mold at a factory. In addition, Integra recently received a warning letter from the US Food and Drug Administration (“FDA”) pertaining to quality systems and compliance issues at its collagen manufacturing facility in Plainsboro, New Jersey. Earlier in August, the company received a Form 483 observation from the FDA regarding manufacturing concerns at this collagen manufacturing facility. Collagen products currently represent roughly 23% of total sales and are manufactured at two facilities (the second in Puerto Rico).

If you are aware of any facts relating to this investigation, or purchased shares of Integra, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email Those who inquire by e-mail are encouraged to include their mailing address and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate work, private securities offerings, and securities arbitration.

If you liked this article you might like

Johnson & Johnson Signals It Could Make Additional Divestitures

Integra's Massive Run-Up Expected to Continue as J&J's Surgical Business Joins the Fold

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion

Derma Sciences Soars Almost 40% on Buyout by Integra